2[2]Rehman HU,Mohammed K.Perioperative management of diabetic patients.Curr Surg,2003,60(6),607-611.
3[3]Tanabe N,Ishill M,Sato Y,et al.Effects of Colateral vessel occlusion on oral glucose tolerance test in liver chirrosis.Dig Dis Sci,2000,45 (3):581-586.
4[4]Muller MJ,Pirlch M,Balks HJ,et al.Glucose intoleance in liver cirrhosis:role of hepatic and nonhepatic influences.Eur J Clin Chem Chin Biochem,1994,32(10):749-758.
5Ottesen JL, Nilsson P, Jami J, et al, The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia, 1994,37:1178-1185.
6Edmond A R, Shardeen I, Clarissa W. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes [J]. Diabetes Care, 2004,27 : 1028-1032.
7Genuth S,Eastman R,Kahn R,et al. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study [J]. Diabetes Care, 1988, 21:2180.
8Inzucchi SE. Management of hyperglyceraia in the hospital setting[J]. N Engl J Med, 2006, 355(18): 1903.
9Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy,safety,quality of life,and cost-effectiveness [J]. Diabetes Metsb Res Rev, 2004, 20(3): 178-188.
10Edmond AR, Shardeen I, Clarissa W. Term intensive insulin therapy in newly diagnosed type 2 diabetes [J]. Diabetes Care, 2004, 27: 1028-1032.
